Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Immix Biopharma reported a 95% complete response (CR) rate in its NEXICART-2 Phase 2 trial for relapsed/refractory AL Amyloidosis, with 19 of the first 20 patients achieving CR. All four patients who were previously MRD-negative converted to CR, and no relapses have been observed to date among those who reached CR. All subsequently enrolled patients with available results are MRD-negative at one month.
Key figures
- Drug Name
- NXC-201
- Phase Of Trial
- Phase 2
- Patients with cr
- 19
- Patients in cohort
- 20
- Market size 2017 usd
- 3600000000
- Market size 2025 usd
- 6000000000
- Complete response rate
- 95%
- Us rr patient count 2026
- 38500
- Median prior lines of therapy
- 4
- Mr negative patients converted
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.